Antara Approved for New Dosage Strengths

Lupin announced that it has received final approval for its supplemental New Drug Application (sNDA) for new dosage strengths of Antara (fenofibrate) capsules, 30mg and 90mg.

RELATED: Cardiovascular Disease Resource Center

Antara is a fibrate indicated as an adjunct to diet when response to nondrug therapy is inadequate in hypertriglyceridemia (Types IV and V), and to reduce elevated total-C, LDL-C, apo B, and TG, and to increase HDL-C, in primary hypercholesterolemia and mixed dyslipidemia (Type IIa and IIb).

Antara is already available in 43mg and 130mg dosage strength capsules. Lupin will commence marketing the 30mg and 90mg strengths shortly.

For more information call (800) 399-2561 or visit